Pityriasis Rosea of Gibert: A Comprehensive Review of a Common, Self-Limiting Dermatologic Entity

Main Article Content

Monserrat Espinosa Ramos
Maria Reyna Lara Guevara
Salmahk Karen Avilés Tenorio

Abstract

Pityriasis rosea of Gibert is a common, self-limiting dermatologic entity that continues to raise questions regarding its etiology, diagnosis, and clinical management. This comprehensive review focuses on analyzing the distinctive clinical presentation of pityriasis rosea, characterized by the appearance of a herald patch followed by multiple secondary collarete or Christmas tree lesions. Although the exact cause of this disease remains unknown, a possible relationship with an immune reaction triggered by a previous viral infection or environmental factors yet to be identified is postulated.


Through a thorough literature search, current findings on the epidemiology, pathogenesis and clinical diagnosis of pityriasis rosea are evaluated. The importance of the clinician's clinical judgment and accurate identification of the distinctive features of the skin lesions to reach an accurate diagnosis is emphasized.


Although pityriasis rosea is usually asymptomatic or causes mild pruritus in most cases, symptomatic therapeutic options, such as the use of oral antihistamines and low potency topical corticosteroids, are described to alleviate patient discomfort when necessary. Patient education and psychological support are essential to decrease the anxiety associated with skin lesions and to provide reassurance during the self-limiting course of this condition.


In the context of the clinical and epidemiologic relevance of pityriasis rosea, the need for continued research to improve understanding of its etiology and management arises. Although pityriasis rosea does not represent a serious health threat, its high frequency in the population and its distinctive clinical appearance underscore the importance of empathetic and compassionate medical care to ensure the patient's well-being during the process of spontaneous resolution.

Article Details

How to Cite
Monserrat Espinosa Ramos, Maria Reyna Lara Guevara, & Salmahk Karen Avilés Tenorio. (2023). Pityriasis Rosea of Gibert: A Comprehensive Review of a Common, Self-Limiting Dermatologic Entity. International Journal of Medical Science and Clinical Research Studies, 3(8), 1532–1535. https://doi.org/10.47191/ijmscrs/v3-i8-11
Section
Articles

References

I. Chuh A, Lee A, Zawar V, Sciallis G, Kempf W. Pityriasis rosea - an update, Indian J Dermatol Venereol Leprol, 2005; 71: 311-315.

II. Ozge G, Siebel E, Aysen K. Childhood pityriasis rosea, Ped Dermatol, 2009; 26: 750-751.

III. Raspa ML. Pityriasis rosea. In: Larralde M, Abad ME, Luna P, Dermatología pediátrica, 2nd edition, Buenos Aires: Ediciones Journal; 2010: 414-416.

IV. Rebora A, Drago F, Broccolo F. Pityriasis rosea and herpesviruses: facts and controversies, Clin Dermatol, 2010; 28: 497-501.

V. López-Carrera I, Durán-McKinster C, Sáez-de-Ocariz MM, Orozco-Covarrubias L, Palacios-López C, Ruiz-Maldonado R. Pityriasis rosea: an exanthem that should be recognized by the first contact physician. Study of 30 cases, Acta Pediátr Mex, 2014; 35: 289-294.

VI. Gonzalez LM, Allen R, Janniger CK, Schwartz RA. Pityriasis rosea: An important papuloscamous disorder, Int J Dermatol, 2005; 44: 757-764.

VII. Jacyk WK. Pityriasis rosea in Nigerians, Int J Dermatol, 1980; 19: 397-399.

VIII. Drago F, Vecchio F, Rebora A. Use of high-dose acyclovir in pityriasis rosea, J Am Acad Dermatol, 2006; 54: 82-85.

IX. Rassai S, Feily A, Sina N, Abtahian S. Low dose of acyclovir may be an eff ective treatment against pityriasis rosea: a random investigator-blind clinical trial on 64 patients, J Eur Acad Dermatol Venereol, 2011; 25: 24-26.

X. Sharma PK, Yadav TP, Gautam PK, Taneja N, Satyanarayana L. Erythromycin in pityriasis rosea: a double-blind, placebo controlled clinical trial, J Am Acad Dermatol, 2000; 42: 241-244.

Most read articles by the same author(s)